Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Wertheim cung cấp cho các bạn kiến thức về ngành y đề tài: Utilization and spending trends for antiretroviral medications in the . Medicaid program from 1991 to 2005. | BioMed Central AIDS Research and Therapy Research Open Access Utilization and spending trends for antiretroviral medications in the . Medicaid program from 1991 to 2005 Yonghua Jing1 Patricia Klein1 Christina ML Kelton2 Xing Li1 and Jeff J Guo 1 3 4 Address 1College of Pharmacy University of Cincinnati Medical Center Cincinnati Ohio USA 2College of Business University of Cincinnati Cincinnati Ohio USA institute for the Study of Health University of Cincinnati Cincinnati Ohio USA and 4Professor of Pharmacoeconomics Pharmacoepidemiology Division of Pharmacy Practice and Administrative Sciences University of Cincinnati College of Pharmacy 3225 Eden Ave. Cincinnati OH 45267-0004 USA Email Yonghua Jing - jingy@ Patricia Klein - kleinpa@ Christina ML Kelton - Xing Li - lix8@ Jeff J Guo - Corresponding author Published 16 October 2007 Received 2 June 2007 AIDS Research and Therapy 2007 4 22 doi l742-6405-4-22 Accepted 16 October 2007 This article is available from http contentM 1 22 2007 Jing et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background HIV AIDS incidence and mortality rates have decreased in the . since 1996. Accompanying the longer life spans of those diagnosed with the disease however is a tremendous rise in expenditures on medication. The objective of this study is to describe the trends in utilization of spending on and market shares of antiretroviral medications in the . Medicaid Program. Antiretroviral drugs include nucleoside reverse transcriptase inhibitors NRTIs protease inhibitors PIs nonnucleoside reverse transcriptase inhibitors NNRTIs and fusion inhibitors FIs . Methods .
